Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MAGE-A3 ASCI · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| NMIBC at intermediate risk of progression | EXPERIMENTAL | - |
| NMIBC at high risk of progression | EXPERIMENTAL | - |
| NMIBC at low risk of progression | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MAGE-A3 ASCI | BIOLOGICAL | 5 doses every 3 weeks |
| BCG | BIOLOGICAL | 1 intravesical dose /week for 6 weeks |
Inclusion Criteria: * Male or female patient with histological confirmation of NMIBC * Full recovery from surgery (TUR) from 1 to 6 weeks * Karnofsky performance status of 60% or more * Laboratory parameters for vital functions should be in the normal range * Women of childbearing potential must us...
Top 20 of 46 competitors
MAGE-A3 ASCI is an investigational antigen-specific cancer immunotherapeutic being studied for the treatment of non-muscle invasive bladder cancer (NMIBC). It is designed to be used in combination with BCG therapy to modulate the immune response in patients with this condition.
MAGE-A3 ASCI targets the MAGE-A3 tumor antigen, which is expressed on various cancer cells. The therapy is designed to stimulate the immune system to recognize and attack cells presenting this antigen, potentially leading to an anti-tumor immune response.
MAGE-A3 ASCI is being developed by GSK plc, a global biopharmaceutical company listed on the London Stock Exchange under the ticker GSK. The company is investigating this therapy as a potential treatment option for bladder cancer.
MAGE-A3 ASCI is in Phase 1 clinical development. It is an investigational drug that has not been approved by regulatory authorities. The therapy is currently being evaluated in early-stage clinical trials to assess its safety and preliminary efficacy.
MAGE-A3 ASCI has been studied in one completed Phase 1 clinical trial, identified as NCT01498172. This trial evaluated the combination of BCG with recMAGE-A3 plus AS15 ASCI in patients with non-muscle invasive bladder cancer. The trial enrolled 23 participants and was conducted in Switzerland.
MAGE-A3 ASCI is also known as recMAGE-A3 when combined with the AS15 adjuvant system. The clinical trial NCT01498172 refers to the therapy as recMAGE-A3 + AS15 ASCI, indicating that MAGE-A3 ASCI is the antigen-specific cancer immunotherapeutic component of this combination.